An announcement from Icecure Medical ( (ICCM) ) is now available.
In 2024, IceCure Medical saw a 42% increase in North American sales of its ProSense® cryoablation system, indicating growing adoption for treating breast tumors. The company completed a decade-long ICE3 study, which showed high patient satisfaction and a significant recurrence-free rate, leading to a favorable FDA Advisory Panel vote. IceCure anticipates FDA market authorization for early-stage breast cancer treatment in 2025, potentially boosting sales and global adoption. The company also expanded its board, fortified its intellectual property, and achieved regulatory clearance for its XSense™ system. These developments position IceCure strategically for future growth and increased market presence.
More about Icecure Medical
IceCure Medical Ltd. is a developer of minimally-invasive cryoablation technology designed to destroy tumors by freezing, offering an alternative to surgical tumor removal. Their primary product, the ProSense® Cryoablation System, targets benign and cancerous lesions, including those in the breast, kidney, lung, and liver, providing a less invasive option for patients and healthcare providers.
YTD Price Performance: 6.10%
Average Trading Volume: 752,558
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $71.49M
For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.